Objective : Oestrogen-hypothesis in schizophrenia is a largely debated issue. Being a multifactor disorder, schizophrenia has gained importance in the field of psychiatric research, especially to dig out the tentative aetiologies (genetic, biological, environmental etc.), still under tested or not tested. The present article is an attempt only to understand the possible role of oestrogen as a 'core' biological factor at the backdrop of male-female differences (in the onset, course, treatment response, prognosis) in schizophrenia barring other factors. This is to reduce the level of 'conflict' and 'confusion' in the article. Method : Electronic data search is the mainstay of the literature bank, included in the article and only 'supportive' evidences (direct and indirect) are incorporated to understand the role of oestrogen in the brain at the backdrop of schizophrenia. Result: The study comes out with a postulation that oestrogen has got a potential effect in moderating the process of schizophrenia in the females.
INTRODUCTION
'Sex bias' in schizophrenia is an ever interesting and well-nurtured topic, because it imparts a significant effect in the heterogeneirv of schizophrenic population. Amidst so many controversies, the 'bias' stands on the basis of the observation that males usually develop the illness early (Chaves et al, 1993) , sustain a more vulnerable course and often suffer from poorer prognosis than females (Meyer er al, 1993) . On the other hand, females manifest the illness during their lifetime when the serum oestrogen level is low, for e.g. at the particular phase of menstrual cycle (Riecher-Rossler et al, 1994) , after the childbirth (Davies et al, 1995) and after menopause (Hafner er al, 1993) .
Among much possible aetiology in schizophrenia, it has been seen that birth-related complications lead to the development of schizophrenia in the susceptible babies (Chattopadhyay & Mandal, 2001 ). Now, the question comes, despite of equal vulnerability of development of schizophrenia in both the sexes at birth, why male babies show such preponderance? To answer the question, the present article is focused on the tentative roles of oestrogen, a potent pleiotropic hormone, responsible for the socalled "feminity"-a principal biological discriminator between two sexes. Other possible aetiological components (genetic, anatomical variations, environmental factors, stress etc.) are excluded from this article to concentrate only on the tentative role of oestrogen behind the sex-related-heterogeocity in schizophrenia.
METHOD
Electronic data search through PubMed Entrez for reviewing the available and relevant literature of last two decades with the special reference of the updated concepts and current studies on oestrogen in schizophrenia. Among the studies, only the supportive evidences (empirical and review) have been included in the present paper to understand the function of oestrogen at the backdrop of schizophrenia' for getting a maximally focused view on it.
RESULT
The literature search finds that oestrogen has gained tremendous significance in die field of biomolecular research because of its pleiotropic nature. It manipulates the pathophysiology of several diseases including psychiatric illnesses probably through its nuclear receptor gene expression (oestrogen has got a nuclear receptor).
Genetic modeling of oestrogen-metabolism shows that oesrrogen is responsible for manipulation of diseases like breast, ovarian and colorectal cancers, PCOD (Polycystic ovarian Disease), Parkinson's disease, alcoholism and schizophrenia (Huber et al, 2002) . Further, psychobiological implications of oestrogen withdrawal in Postmenopausal syndrome are well-known facts. Impact of oestrogen on the psychobiology of females has direcily been supported by the fact that oetrogen-therapy combats the adverse psychological symptoms in the postmenopausal females (Ozsoy et al 2002) Apart from that, oestrogen (transdermal) also has been found to be beneficial to liting down the psychiatric symptoms of puerperal psychosis (Gregoire et al, 1996) , an encouraging impact on the symptoms of schizophrenic females (Kulkari et al, 2002) , alleviating PCOD related psychological disorders (Kopala et al, 1997 ) and the premenstrual tension (Tiemsrra & Patel, 1998) . Recent studies have showed that oestrogen replacement therapy' improves the mood, memory and mental status in schizophrenic females at a large (lindamer et al, 1997) mostly in conjunction with antipsychotics (Kulkari et al, 2001; Gregoriadis & Seeman, 2002) , though effects may van-from individual to individual (Liao et al, 2002) . Gregoriadis & Seeman, (2002) also observed that oestrogen supplementation along with the antipsychotics prevent the occurrence ot tardive dyskinesia, a very common side effect of antipsychotic medication.
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IS OESTROGEN A-BIOLOGICAL NEUROLEPTIC!
Level of serum oestrogen has got a strong correlation with the cognitive function especially global cognition, verbal, spatial decelaration memory and perceptual motor speed and higher oestrogen levels in female schizophrenics are associated with the better cognitive ability (Hoff et al, 2001 ). While evaluating the molecular process of such "oestrogenic effect" in the brain, GarciaSegura et al, (2001) found that oestrogen prevents several neurodegenerative processes by virtue of its nuclear receptor mediatedalteration of oestrogen-responsive-geneexpression that modulates the rate of apoptosis, axonal degeneration and a generalized support to the neurons. Now, if oestrogen has got modifying effect on the neuropsychiatric process in females then how it acts in the brain, especially in schizophrenia? The answer of it probably lies on the fact that oestrogen must have some modulating role on dopamine and serotonin receptors in the relevant part of the brain, affected in schizophrenia, as excessive dopamine and serotonin, discharges in the mesocortex and mesolimbic areas are one of the established parthophysiology behind the onset of schizophrenia (Carpenter & Buchanan, 1995) . in support to the postulation, following animal studies have been reviewed to understand the biomolecular mechanisms of ocitrogenie action in the brain.
Using animal models, studies of Gattaz er al. (1992) and Bosse & Di Paolo, (1996) showed that oestrogen is a potent dopamine receptor blocker, especially D, and D 2 . A series of studies of Fink et al. (1996) , Fink et al. (1998) , Fink, (1998), Fink et al. (1999) , Osterlund et al. (2000) documented that oestrogen can also block serotonin receptors too, especially 5HT |A and 5 "»• CONCLUSION Therefore, oestrogen, by blocking the dopamine and serotonin receptors in the brain probably serves alike neuroleptics, which are either purely dopamine blockers (chlorpromazine, haloperidol, clozapine etc.) or dopamine plus serotonin blockers (Risperidone). Therefore, it could be postulated that oestrogen, by blocking the dopamine and serotonin receptors in the brain probably serves like neuroleptics in females (due to its natural abundance). Given such documentarions it seems that oestrogen could be a natural psycho protectant in femalesl and it needs to be tested further.
Strategy for the future research to reevaluate the effect of oestrogen on schizophrenia could be:
A. Clinical trial
First episode female schizophrenics may be tried with oral or transdermal oestrogen (available standard daily dose) alone for a particular period of time (may be for first three cycles or even beyond that according to dose-response graph) and symptomvariation could be noted using BPRS (Brief Psychiatric Ratting Scale) and Hamilton's Rating Scale For Depression (HAM-D).
Patients who do not respond may be added antipsychotic medication its the lowest possible dosage and the symptoms are rated using Nurse's Observation Scale. 'Observations' and 'ratings' of the changes in the symptoms including the adverse effects of the drugs used should be marched with the serial estimation of serum oestradiol (the most potent among the biologically available oestrogen to titrate the most effective dosage of oesrrogen or oestrogen plus antipsychotics.
B. Utilization of Nuclear Imaging Techniques
Nuclear Imaging Techniques like PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography.) or fMRI (Functional Magnetic Resonance Imaging) could be the useful adjunct to suds clinical study by providing (i) the rate of receptor occupancy (dopamine and serotonin in the relevant areas in the brain) by oestrogen could be tallied with the syospromatic improvement, especially the maximum and the plasma oestrogen level at that time, ii) delineation of the change of metabolism of those parts, possibly affected by oestrogen, matched with the possible therapeutic benefit, and III) measurement of most effective dosage of oestrogen in the treatment of (A schizophrenia.
